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ABSTRACT OF THESIS

THE INFLUENCE OF ANTIDIABETIC MEDICATIONS ON THE DEVELOPMENT
AND PROGRESSION OF PROSTATE CANCER

The development of prostate tumors has been linked to co-morbid
diabetes mellitus (DM) in several studies, potentially through the stimulation of
insulin-like growth factor receptor (IGFR). This study evaluates the effect of antidiabetic medication use on the development of high grade tumors and time to
tumor progression compared to non-diabetics. This retrospective, nested case
control study identified patients with prostate cancer (PCa) from the Kentucky
Medicaid Database. Cases were diagnosed with PCa and DM and using at least
one of the following antidiabetic medications; sulfonylureas, insulin, metformin or
TZDs. Cases were further stratified on their insulin exposure resulting from
therapy. Controls were those with PCa without DM or any anti-diabetic
medications. No statistically significant effects on insulin exposure was found on
tumor grade and time to progression. Trends identified that use of metformin or
TZDs potentially decreased the odds of high-grade tumors and decreased the
risk of progression, while sulfonylureas and high-dose insulin may increase the
odds of high-grade tumors and increase the risk of progression compared to nondiabetics. Future studies should be conducted to further evaluate the effects of
anti-diabetic medications on tumor grade and time to prostate cancer
progression.
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SECTION ONE: BACKGROUND

Prostate cancer (PCa) is the most common cancer of men in the United States,
affecting nearly 2.4 million men in 2008.1 Currently 11.8% of the adult male
population (13 million men) are estimated to have a diagnosis of diabetes, 9095% of which is considered to be type II (T2DM).2 While the most prominent long
term effects of diabetes are cardiovascular complications, recent studies have
demonstrated a relationship between diabetes, diabetes treatments and cancer
risk.3-9

In investigating the association, the presence of diabetes was found to
independently correlate with lower prostate specific antigen (PSA) levels.10
Looking at how this may translate into overall cancer risk, the Physician’s Health
Study found that diabetics were 36% less likely to develop prostate cancer than
non-diabetics, a finding that has been supported in other trials.3,6,11,12
Interestingly, the duration of diabetes diagnosis also appears to affect this
relationship, with those with long-standing T2DM having a lower risk than newly
diagnosed patients, namely due to the progressive nature of insulin
resistance.13,14 Furthermore, in those that do develop cancer, diabetes appears
to have an effect on tumor grade, with some studies reporting a direct
relationship in prostate tumors while others demonstrate inverse correlation.6,15-19
Although numerous hypothesis have been proposed to explain this causal
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relationship, one prominent rationale focuses on the role of insulin exposure and
the insulin-like growth factor receptor (IGF-1R) in tumorgenesis.4,5,7

Insulin-like growth factor

IGF-1R is a dimeric type 2 tyrosine kinase receptor expressed on both normal
tissue as well as numerous cancer cell lines. It is structurally similar to the insulin
receptor (IR) and may form hetero-dimer hybrids with IR on cells that co-express
both receptors.20,21 Stimulation of IGF-1R is associated with numerous
downstream actions including the activation of mitogenic and anti-apoptotic
mechanisms such as the P13K/AKT and RAS/RAF/MAPK signaling pathways,
stimulation of which have a known effect on oncogenesis. These activations are
essential in cell growth, proliferation and survival; mutations in these pathways
have been shown to lead to aberrant uncontrolled cell growth.22 The effects of
IGF-1R and its primary ligand, insulin-like growth factor (IGF-1) on the
development of cancer have been evaluated in numerous cell and animal
models.21-24

Specifically IGF-1R, insulin receptors and hetero-dimers have been shown to be
over-expressed in both normal and malignant prostate tissue. Studies have
demonstrated a trend of increasing levels of expression being associated with
increased levels of prostate specific antigen (PSA) and higher Gleason score
values, both of which indicate increased aggressiveness and poorer prognosis.25-
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Recent evaluation of IGF-1R antagonism in prostate tumor cells has

demonstrated a decrease in both androgen dependant and androgen
independent cell growth, furthering the hypothesis that IGF-1R activation may
accelerate tumor progression.23

While IGF-1 is the most common cause of IGF-1R stimulation, insulin has also
been demonstrated to bind and activate the IGF-1 receptor, leading to increased
cellular proliferation and anti-apoptosis.21,22,28 Increased measured insulin levels
have been linked to not only a higher incidence of prostate cancer, but also
potentially increased Gleason scores and cancer-related mortality.7,16,29 Lehrer et
al. found that men presenting with higher grade tumors had higher measured
circulating insulin, although the diabetic status of these patients was not noted.16
Further in a study by Venkateswaran et al. mice with a diet-induced measured
hyperinsulinemic state had an increase in prostate tumor size over those with
normal levels.30 These studies support the hypothesis that the acute elevation in
insulin seen in initial diabetes development impacts tumor growth, while the
overall long term decrease in circulating insulin affects tumor development.

Serum insulin levels and PCa

Antidiabetic pharmacotherapy can influence the levels of exogenous and
endogenous insulin, potentially impacting tumor development.31 Weinstein et al.
found that insulin analogues (glargine, detemir) increased mitogenic growth
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similar to direct application of IGF-1 on tumor cells. In these cells, the rate of
proliferation increased by 14-16% in glargine and detemir treated cells, while the
percentage of apoptotic cells decreased by 5.1-8.3% compared to controls
(p<0.05).28 This finding was confirmed in an epidemiologic study by Hemkens et
al. that found a dose-dependent OR 1.09-1.31 times (p<0.0001) greater risk of
cancer for those using insulin glargine over regular human insulin.32 This
increase in cellular proliferation, especially prominent with the increased
exposure of longer acting agents provides further evidence of the relationship of
insulin and prostate cancer cell growth.

Looking at the use of oral agents, conflicting data exists regarding the role that
oral anti-diabetic agents play in the development of prostate tumors. Bowker et
al. linked the use of insulin and insulin-secretagogue agents (i.e. sulfonylureas)
with an increased risk of cancer-related mortality across all cancer types.
Patients with any use of sulfonylureas had a 1.3 times higher cancer-related
mortality than those on metformin, a non-secreting agent, while any use of insulin
increased the risk by 1.9 times versus non-insulin users.33 Compared to insulinstimulating agents, thiazolidinediones (TZDs) appear to have little to no effect on
the development of any cancer type, although the results are inconsistent.34,35

Specifically evaluating prostate tumors, Murtola et al. reported a lower risk of
prostate tumor development with all users of oral antidiabetic therapy (metformin,
sulfonylureas, or other oral agents) compared to non-diabetic non-users,
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although this did not differentiate between disease effect versus the effect of the
medications used to managed diabetes. Currie et al. reported a non-statistically
significant increase in prostate cancer risk for those treated with sulfonylurea
monotherapy, sulfonylurea + metformin therapy or insulin-based therapies
compared to those using metformin as a single agent.36 On the contrary, a large
cohort analysis from the Kaiser Permanente Northern California Diabetes
Registry, the ever-use of any oral antidiabetic therapy (sulfonylureas, metformin
and TZDs) was not associated with any change in the development of prostate
tumors.37 From this information it is clear that the interaction of these agents with
tumor development and growth is unclear and more investigation is needed to
guide prudent medication selection in diabetic men at-risk for prostate tumors.

Covariate relationship

In addition to these observed relationships, other factors may also impact the
complex interactions of prostate cancer and diabetes and should be accounted
for in future study. Bisphosphonates are often used to prevent and treat bone
metastases and may reduce the adhesion and invasion of metastasized tumor
cells, potentially prolonging the time to progression.38 Other concurrent
medications, such as corticosteroids, are commonly used in the management of
prostate tumors and may lead to hyperglycemia.39 The increased presence of
serum glucose stimulates insulin production in non-diabetic patients and may
necessitate increased medication doses in diabetic patients. Additionally, recent
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research has suggested that obesity, hypertension, hypercholesterolemia, either
individually or as metabolic syndrome may also play a role in the development of
higher-grade cancer (Gleason score ≥ 7) as well as increased progression.8,40
These findings appear to be independent of concurrent diabetes and are thought
to potentially be through alterations in sex-hormones.8 Finally, use of androgen
deprivation therapy (ADT) in the treatment of prostate tumors has also been
linked to the increased development of diabetes and metabolic syndrome in
previously undiagnosed patients and may also affect tumor development.41

Aside from concurrent medication use and medical diagnoses, social factors may
also influence the development and progression of prostate cancer. Numerous
studies have cited that patients living in more rural areas have reduced access to
health, leading to poorer outcomes across disease states. Specifically, how far
patients live from their treating physician has been associated with worsening
overall glycemic control and may impact the presence of serum insulin.42 In
regards to prostate cancer outcomes, men in rural areas away from treatment
centers are less likely to undergo more aggressive radiation therapy as those
living in more metropolitan areas.43,44 In addition to the decreased access to care
seen in rural patients, other, non-medical exposures may also impact the
characteristics of prostate tumors in more agrarian areas. While not commonly
encountered, several occupational investigations have cited that farmers have an
increased risk and mortality of prostate tumors.45-47
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The relationship between insulin, diabetes and prostate cancer is complex with
multiple modifying factors. An improved characterization of this association on
the development and progression of prostate tumors could potentially impact
thousands of patients. Based upon previous epidemiologic, animal and in vitro
studies we hypothesize that increased insulin exposure induced by endogenous
insulin or oral insulin secretagogues will increase the initial tumor invasiveness
as measured by Gleason score and shorten the time to disease progression.

SECTION TWO: METHODS

Study Design

This was a retrospective nested case-control study of the Kentucky Medicaid
population. The Kentucky Medicaid (KM) database contains billing information on
the healthcare utilization, including procedures, medication use and diagnoses,
of low-income patients. Data within the KM database is available through the
International Disease Classification 9th revision (ICD-9) and Current Procedural
Terminology (CPT) codes. Data prior to January 1, 2000 was not available and
after December 31, 2005, outpatient prescription drug coverage of patients >65
years of age was transitioned to coverage through the national Medicare Part D
program and was no longer available through the Kentucky Medicaid (KM)
database.
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In addition to information from the KM database, the Kentucky Cancer Registry
(KCR) was also used for data collection and validation. The KCR is a mandatory
state cancer reporting system that is part of the National Cancer Institute’s
Surveillance Epidemiology End Results (SEER) program. All state healthcare
facilities are required by law to report all new cancer diagnoses to the registry.
Through participation in SEER, cases are validated and additional demographic,
pathologic, and survival information is collected.48

This study protocol was reviewed and approved through the Institutional Review
Board (IRB) at the University of Kentucky and the Kentucky Cabinet for Health
and Family Services (KCHFS). An independent board at the Kentucky Cancer
Registry also approved the use of this protocol upon recommendation from the
University of Kentucky and KCHFS.

Study Population

All male patients >18 years age who were found to have a diagnoses of prostate
cancer between July 1, 2000 and December 31, 2005, as defined below, were
established for inclusion. Patients were followed from diagnosis until the last date
of contact or August 31, 2009, whichever came first. Patients must have had
Medicaid enrollment for >11 months to allow for medication use analysis.
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Diagnosis of prostate cancer was determined through the identification of the
ICD-9 diagnosis codes for primary prostate gland cancer (PGC) (ICD9 185.x)
and primary prostate utricle cancer (PUC) (ICD9 189.3) within the KM database.
Patients with benign lesions or carcinoma in situ were excluded. Patients must
have had at least two cancer related visits to a healthcare provider within 1 year.
Patients with a diagnosis of prostate cancer through the KM database were then
linked to information from the KCR to validate diagnosis dates and provide
pathologic and staging data. In the event of a discrepancy for diagnosis date
between the two databases, the date given by KCR was utilized due to the
independent validation of this dataset.

Diagnosis of diabetes mellitus was determined using the Healthcare
Effectiveness Data and Information Set (HEDIS) definition. Patients with two type
II diabetes (T2DM) related healthcare visits (defined by the presence of ICD
250.x2 or 250.x0) and a prescription for an antidiabetic medication filled within 1
year were considered to have diabetes. The presence of type I diabetes was not
eligible for study inclusion due to the lack of endogenous insulin and inability to
use oral antidiabetic medications of this patient population.

Insulin exposure groups were determined based on the use of antidiabetic
medications within the KM database. Medications were determined through the
use of NDC codes; a complete list of medications used within the study is
available in Appendix Table 1.. Patients with the use of sulfonylureas, insulin at
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doses >0.8 units/kg/day (high-dose; utilized an average weight of 85kg
determined from internal data on the weight of prostate cancer patients in
Kentucky) or combination therapy for >2/3 the entire study period involving either
of these agents were considered to have elevated insulin exposure. Patients
using metformin, TZDs, insulin at doses ≤0.8 units/kg/day, or combination
therapy for >2/3 of the study period without high-dose insulin or sulfonylureas
were considered to have physiologic insulin exposure. Those without the use of a
clear combination medication therapy for >2/3 the study period, one-time
medication use or poor diabetes medication compliance were considered to have
indeterminate insulin exposure. Patients without a diagnosis of type I or type II
diabetes, or the receipt of an antidiabetic medication at any time during the study
observation were considered control subjects. Since age is a key determinate in
the progression of aggressive of prostate tumors and a well known confounder,
cases were age-matched to controls in randomized blocks of 2, allowing for up to
2 controls present in the analysis for every case.

Patients with an ICD-9 diagnosis of diabetes, but who do not have a prescription
for diabetes treatment during the study period were excluded. These include
patients who may be utilizing therapeutic lifestyle changes for glucose control
and may have less predictable insulin exposure. Patients utilizing therapy with
repaglinde, nateglindine, α-glucosidase inhibitors were not included due to
variable insulin exposure. Newer agents such as exenatide, pramlintide or
sitagliptin were not present in the Medicaid population during the study period.
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In addition to the diagnosis of prostate cancer and diabetes, information on age,
presence of diabetes, medication use (including steroid and bisphosphonate
use), geography, comorbid disease, tumor grade, tumor stage, metastatic sites,
surgical information, time with diagnosis of diabetes within the study period and
compliance was collected. Medication use was defined as use prior to diagnosis
(for primary analysis) or recurrence (for secondary analysis); steroid use was
limited to those with use for ≥30 days. Geography was determined through the
use of the United States Department of Agriculture (USDA) Rural-Urban
continuum codes.49 Based on their primary residence, patients were divided into
urban, suburban and rural areas based on their proximity to large metro areas.
Co-morbid disease was primarily measured in the KM database through the use
of the Charlson score. The Charlson score is a weighted composite score that
evaluates the presence of 22 conditions (e.g. heart disease, hypertension,
pulmonary dysfunction, diabetes, AIDS, renal dysfunction, etc.).50 For this
analysis, the Charlson score calculated prior to the diagnosis of cancer was
utilized to reduce falsely elevated comorbid disease. Charlson data was not
available for all patients, so in addition the the presence of a hypertension or
hypercholesterolemia diagnosis in the Medicaid database with subsequent
prescription medication treatment was also included as a separate measure of
comorbid disease Medication Possession Ratio (MPR) was used to evaluate
medication compliance of diabetes medications and determine study inclusion.
MPR is calculated as the sum of the days supply medication over a time period
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divided by the time period of evaluation.51 An MPR of <80% was used to
determine poor diabetes medication compliance and led to study exclusion.

Determination of endpoints
Gleason score information is available as part of the KCR database from
pathology reports at the time of diagnosis. Patients with a Gleason score <7 were
considered to have low grade, less aggressive disease while those with a
Gleason score ≥7 were considered to have high grade, more aggressive tumors.

Time to progression was defined as a composite endpoint classified through the
use of ICD-9 and CPT codes within the KM database. Patients that experienced
any of the following events ≥ 60 days after the diagnosis of prostate cancer were
considered to have progressed:
1. Appearance of elevation of PSA ICD-9 code (790.93) at any point after the
index date of PSA normalization.
2. Initiation of chemotherapy determined through CPT codes 96401-96549 or
the presence of chemotherapy within the KM prescription database (low
dose oral methotrexate was excluded).
3. Development of a secondary cancer diagnosis in patients who were not
diagnosed at a metastatic stage. This was determined through ICD9
codes and based on reasonable sites of metastatic spread of prostate
cancer including bone/spine, regional lymph nodes, bladder, kidney, liver,
lung, colon/rectum and other pelvic/genital structures.52
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Statistical Analysis

Demographic variables were evaluated using descriptive statistics. Simple
comparisons of continuous variables between the study groups was conducted
using ANOVA testing for normally distributed data and Kruskal-Wallis testing for
non-parametric variables. Categorical variables were evaluated using chi-square
testing of independence; however, when low cell counts were found, Fisher’s
exact testing was utilized instead.

The primary endpoint was the presence of low Gleason score at diagnosis. An
odds ratio of the presence of low Gleason score between cases and controls was
evaluated through bivariate and multivariate conditional logistic regression to
control for confounders. Conditional logistic regression allows for comparison
between matched groups; using this test provided for appropriate analysis
between the age-matched cases and controls. The conditional multivariate
regression included known confounders of geography, comorbidity measure and
steroid use prior to diagnosis regardless of the results of the bivariate model. The
secondary endpoint was the time to progression as defined above. Kaplan Meier
survival curves and log-rank testing was used to evaluate the differences in time
to progression between insulin exposure groups. To account for potential
confounding covariates, a Cox Proportional Hazard regression model was
created to evaluate the overall hazard ratios, again accounting for known
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confounders of geography, comorbidity, stage/metastatic spread, and steroid and
bisphosphonate use prior to recurrence. Patient with missing data used in the
regression models were excluded from the regression analysis. Statistical
analysis was performed using STATA v.10 (StataCorp LP, College Station, TX,
USA).

SECTION THREE: RESULTS

Out of 1272 patients initially identified, 722 patients were eligible for inclusion. A
diagram of exclusion is provided in Figure 1. Of these patients, 50 were found to
have physiologic insulin exposure, 103 had elevated insulin exposure, and 16
had indeterminate exposure. The remaining 569 patients had no evidence of
diabetes. From this, 338 were randomly age-matched and selected as controls.
Those with indeterminate exposure were excluded from the final analysis due to
low numbers, leading to a total of 491 patients evaluated. Demographic
information is listed in Table 1.

Within the 491 patients, 236 were found to have evaluable pathologic
information, including Gleason score, provided by the Kentucky Cancer Registry.
One-hundred forty-nine (59.36%) were found to have a low Gleason score (<7),
while 102 (40.64%) were diagnosed with high-grade disease. A breakdown of
this by insulin exposure group is in Figure 2. Overall diabetic patients, regardless
of insulin exposure, presented with lower Gleason scores, although this was not
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statistically significant. Compared to those without diabetes, patients with
elevated exposure had a 5% lower odds (95% CI: 0.47-1.91; p=0.887) of
developing high-grade disease, while those with physiologic exposure had a 45%
lower odds (95% CI: 0.21-1.46; p=0.233). When adjusted for geography, comorbidity (measured as Charlson score), and corticosteroid use prior to prostate
cancer diagnosis, elevated insulin exposure appeared to slightly increase the
odds of presenting with high-grade disease (OR=1.04 (0.44-2.44); p=0.685),
while physiologic insulin exposure decreased the odds (OR=0.62 (0.22-1.70);
p=0.929) compared to controls (Table 2).

Only 299 patients had complete information using the Charlson score as the
measure of comorbidity; 133 had evaluable Gleason scores. Eliminating the
Charlson score measure of comborbidity from the model to increase the
evaluable population to 236, both elevated and physiologic insulin exposure was
found to slightly lower the odds of being diagnosed with a low Gleason score
(Appendix Table 2). Hypercholesterolemia and hypertension are the most
clinically significant comorbid diseases; through the substitution of these
variables as the measure of comorbidity, the evaluable population in the model
was retained at 236 patients, while still allowing for adjustment of the effect of
comorbid disease. Through this, elevated insulin exposure appeared to have no
effect on high-grade disease, while physiologic insulin exposures trended to
lower Gleason scores at diagnosis (elevated insulin OR=1.00 (0.49-2.08);
p=0.988) (physiologic insulin OR=0.59(0.22-1.60); p=0.304)) compared with
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those without diabetes. (Appendix Table 3). Additionally, the duration of diabetes
diagnosis prior to prostate cancer was also evaluated, but was found to have a
non-significant impact on the development of high-grade prostate cancer
(Appendix Table 4).

Evaluating the secondary endpoint (Figure 3), 122 patients were found to have
recurrence. Median time to recurrence was 31.4 (0.03-98.1) months for those
with physiologic exposure compared to 27.6 (1.38-92.7) months for those with
elevated insulin exposure and 26.6 (0.92-96.2) for those without diabetes
(p=0.8623). Adjusting for potential confounders, there was no significant effect of
insulin exposure on the time to tumor progression, although it appeared that
elevated insulin exposure may increase the risk of progression, while physiologic
exposure decreases the risk of progression compared to non-diabetics (Table 3).
Only the use of steroids prior to recurrence was found to have a statistically
significant impact on the time to tumor progression. A 68% decrease (p=0.019) in
the risk of progression over the five years studied was found in patients that used
corticosteroids when controlling for other factors.

Similar to the primary endpoint analysis, the covariates containing incomplete
data were eliminated from the model to improve the evaluable population. In
eliminating the effects of Charlson score and stage, the use of bisphosphonates
was found to increase the risk of recurrence by 1.21-4.59 times compared with
those that did not have bisphosphonate exposure (p=0.001-0.012) (Appendix
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Tables 5-6). Adjusting for comorbidities and stage through evaluating
hypercholesterolemia, hypertension, and the presence of metastases at
diagnosis revealed similar effects. Bisphosphonate use appeared to significantly
increase the risk of progression, despite controlling for comorbidities. Within this
analysis, bisphosphonates were used across all stages of disease. Further
investigation of interaction between Charlson score and bisphosphonate use
demonstrated no interaction. (Appendix Table 7)

Finally, the duration of diabetes prior to prostate cancer development appeared
to increase the risk of progression by 30% for every year diagnosed (95% CI:
1.09-1.73; p=0.007), although this analysis was only available in a small
population (Appendix Table 8).

In evaluating the effect of the presence of DM, regardless of medication use, on
cancer development and progression, diabetics appeared to have no difference
in the grade of tumor at diagnosis, but may have reduced risk of progressive
disease when HTN and hypercholesterolemia are controlled for. The complete
analysis of the effects of DM regardless of medication treatment can be found in
Appendix Tables 9-16.
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Figure 1: Patient selection for cases and randomly selected controls

Male patients with diagnosis of
prostate cancer in the KM database
(n=1272)

Age > 18
(n=1269)

Patients with outpatient prescription
medication information
(n=863)

Diagnosis of DM prior to recurrence
(n=853)

Both diagnosis of DM and use of
prescription therapy
(n=761)

Antidiabetic MPR >80%
(n=722)

Elevated
insulin
exposure
(n=103)

Indeterminate
insulin
exposure*
(n=16)

Physiologic
insulin
exposure
(n=50)

* Patients with indeterminate exposure were excluded from the final analysis
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Randomly agematched
controls
(n=338)

Table 1: Patient Demographic Information
Elevated
insulin
exposure
103 (20.98%)
70.8 (±9.78)

Table 1: Patient Demographic Information continued on page 20
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N
Age, years (mean,SD)
Geography
Urban 32 (31.07%)
Suburban 16 (15.53%)
Rural 55 (53.40%)
Stage*
n=62
Localized 46 (74.19%)
Regional 4 (6.45%)
Distant Metastases 7 (11.29%)
Unknown/unstageable 5 (8.06%)
Presence of metastases at diagnosis
No 96 (93.20%)
Yes 7 (6.80%)
Metastatic sites
No metastatic sites 96 (93.20%)
Bone/Spine 1 (0.97%)
Other sites 6 (5.83%)
Comorbidity Information
Charlson scores (median, 2 (1-7)
range)*
n=86
Presence of Hypertension
No 5 (4.85%)
Yes 98 (95.15%)

Physiologic
insulin
exposure
50 (10.18%)
71.2 (±9.32)

338 (68.84%)
70.6 (±10.18)

491
70.7 (±9.99)

10 (20.00%)
11 (22.00%)
29 (58.00%)
n=30
26 (86.67%)
0 (0%)
2 (6.67%)
2 (6.67%)

96 (28.40%)
61 (18.05%)
181 (53.55%)
n=202
142 (70.30%)
11 (5.45%)
39 (19.31%)
10 (4.95%)

48 (96.00%)
2 (4.00%)

299 (88.46%)
39 (11.54%)

48 (96.00%)
2 (4.00%)
0 (0%)

299 (88.46%)
15 (4.44%)
24 (7.10%)

138 (28.11%)
88 (17.92%)
265 (53.97%)
n=294 0.281
214 (72.79%)
15 (5.10%)
48(16.33%)
17 (5.78%)
0.159
443 (90.22%)
48 (9.78%)
0.119
443 (90.22%)
18 (3.67%)
30 (6.11%)

2 (1-5)
n=40

1 (1-12)
n=173

2 (1-12)
n=299

1 (2.00%)
49 (98.00%)

62 (18.34%)
276 (81.66%)

68 (13.85%)
423 (86.15%)

No evidence
of DM

Total

p-value

0.9250
0.651

0.0351
<0.001

Presence of
Hypercholesterolemia

<0.001
No 51 (49.51%)
Yes 52 (50.49%)

23 (46.00%)
27 (54.00%)

233 (68.93%)
105 (31.07%)

307 (62.53%)
184 (37.47%)

No 90 (87.38%)
Yes 13 (12.62%)

49 (98.00%)
1 (2.00%)

308 (91.12%)
30 (8.88%)

447 (91.04%)
44 (8.96%)

Medication Use
Chemotherapy Use

0.088
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Table 1: Patient Demographic Information continued on page 21

Antiandrogen/GNRH
agonist use

0.869
No 82 (79.61%)
Yes 21 (20.39%)

38 (76.00%)
12 (24.00%)

266 (78.70%)
72 (21.30%)

386 (78.62%)
105 (21.38%)

Bisphosphonate Use
Corticosteroid Useǂ

0.706
No 96 (93.20%)
Yes 7 (6.80%)

No
Before diagnosis
Spanning diagnosis
After diagnosis
Diabetes Information
Time diagnosed with DM,
years (median, range)
Time from diagnosis of
DM to diagnosis of PCa,
years (mean, SD)

48 (96.00%)
2 (4.00%)

311 (92.01%)
27 (7.99%)

455 (92.67%)
36 (7.33%)
0.118

82 (79.61%)
5 (4.85%)
12 (11.65%)
4 (3.88%)

45 (90.00%)
1 (2.00%)
4 (8.00%)
0 (0.00%)

262 (77.51%)
8 (2.37%)
43 (12.72%)
25 (7.40%)

389 (79.23%)
14 (2.85%)
59 (12.02%)
29 (5.91%)

0.346
0.722
0.068

4.2 (0.16-9.61) 3.9 (0.16-9.59)

0 (0)

4.1 (0.16-9.61)

0.5147

1.8 (±1.89)

0 (0)

1.8 (±1.93)

0.8507

1.8 (±2.01)
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Antidiabetic Medication Use
Sulfonylurea use
No sulfonylurea use 10 (9.71%)
Sulfonlyurea + other DM 69 (66.99%)
Exclusive sulfonylurea 24 (23.30%)
Thiazolendione use (TZD)
No TZD use 69 (66.99%)
TZD + other DM med 34 (33.01%)
Exclusive TZD 0 (0%)
Metformin use
No metformin use 48 (46.60%)
Metformin + other DM 55 (53.40%)
Exclusive metformin 0 (0%)
Insulin use
No insulin use 60 (58.25%)
Insulin+ other DM 37 (35.92%)
Exclusive insulin 6 (5.83%)
Average Medication
Possession Ratio (MPR) 1.00 (0.80of Diabetic Meds (median, 4.72)
range)
Use of antidiabetic
medications after PCa dx
14 (13.59%)
(as percent of total
DMgrp)

38 (76.00%)
12 (24.00%)
0 (0%)

338 (100%)
0 (0%)
0 (0%)

386 (78.62%)
81 (16.50%)
24 (4.89%)

<0.001
<0.001

26 (52.00%)
18 (36.00%)
6 (12.00%)

338 (100%)
0 (0%)
0 (0%)

433 (88.19%)
52 (10.59%)
6(1.22%)

<0.001
<0.001

19 (38.00%)
17 (34.00%)
14 (28.00%)

338 (100%)
0 (0%)
0 (0%)

405 (82.48%)
72 (14.66%)
14 (2.85%)

<0.001
<0.001

31 (62.00%)
14 (28.00%)
5 (10.00%)

338 (100%)
0 (0%)
0 (0%)

429 (87.37%)
51 (11.88%)
11 (2.24%)

<0.001
<0.001

0.99 (0.823.53)

0 (0)

1.00 (0.804.72)

11 (22.00%)

0 (0%)

25 (5.09%)

0.7974

*Not available for all patients; number evaluated listed
ǂDifferences between the steroid group overall listed first; differences listed with each point of steroid use (before, during, after) are listed
at the point of use – these were determined from dichotomous values (e.g. used/did not use steroid before diagnosis)

Figure 2: Gleason score based on insulin exposure
100.00%
Gleason score <7

Percent of patients per group with
high/low Gleason scores

90.00%

Gleason score ≥7

80.00%
69.57%

70.00%
60.00%

59.52%

n=16

56.98%

n=25
n=98

50.00%

43.02%

40.48%
40.00%
30.43%
30.00%

n=74

n=17
n=7

20.00%
10.00%
0.00%
Elevated Insulin Exposure

Physiologic Insulin
Exposure
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No Diabetes

Table 2: Multivariate Analysis of Odds of Developing High Gleason Score Based
on Insulin Exposure (n=133)
Odds
Ratio

95% Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.50 (0.17-1.52)
Rural
0.74 (0.30-1.80)
Charlson score
1.07 (0.79-1.44)
Corticosteroid Use (before dx)
No Reference
Yes
1.47 (0.23-9.46)
Diabetes Group
No Diabetes Reference
Elevated insulin exposure
1.04 (0.44-2.44)
Physiologic insulin exposure
0.61 (0.22-1.70)
Physiologic compared to
elevated
0.61 (0.23-1.62)
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0.222
0.500
0.670

0.685

0.929
0.350
0.320

Figure 3: Kaplan Meier Analysis of Time to Progression by Insulin Exposure
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Table 3: Multivariate Analysis of Hazard of Prostate Cancer Progression (n=168)
Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.82 (0.31-2.15)
Rural
0.68 (0.30-1.53)
Charlson score
0.85 (0.62-1.16)
Stage
Localized Reference
Regional
0.96 (0.28-3.30)
Distant Metastases
0.96 (0.36-2.53)
Unknown/unstageable
1.83 (0.42-8.01)
Corticosteroid Use
(prior to recurrence)
No Reference
Yes
0.32 (0.13-0.83)
Bisphosphonate Use
(prior to recurrence)
No Reference
Yes
2.01 (0.64-6.35)
Antiandrogen/GNRH
agonist use
(prior to recurrence)
No Reference
Yes
0.91 (0.43-1.93)
Diabetes Group
No Diabetes Reference
Elevated insulin
exposure
1.18 (0.57-2.44)
Physiologic insulin
exposure
0.62 (0.22-1.73)
Physiologic compared to
elevated
0.58 (0.22-1.53)

25

0.684
0.351
0.313

0.945
0.926
0.421

0.019

0.232

0.814

0.649
0.363
0.272

SECTION FOUR: DISCUSSION
This study found that management of diabetes with medications which create
supra-physiologic insulin exposure does not lead to more aggressive prostate
cancers at diagnosis and shorter time to progression. Previous analyses have
demonstrated a link between diabetes and developing cancer, an effect which is
potentially modified by the choice of antidiabetic treatment.33-37 In vitro studies
clearly demonstrate that insulin can stimulate IGFR-1 receptors in prostate
cancer cell lines and stimulate mitogenic and angiogenesis pathways. These
findings suggest that this isn’t a disease-disease interaction, but rather a disease
treatment – disease interaction. While several others have evaluated the
association of diabetes and cancer, none have evaluated disease management
leading to increased insulin exposure with prostate cancer biology and
progression.

The findings in this analysis are consistent with the work reported by Weinstein et
al. who evaluated the in vitro application of human insulin and human insulin
analogs to prostate tumor cells.28 Here, recombinant human insulin was found to
slightly increase growth, but not significantly when compared to control cells.
When forming the hypothesis, this data was considered, but the in-vivo data
presented by Venkateswaran was more compelling. In this, mice with high
serum insulin were found to have increased tumor growth over those with low
circulating insulin.30 This data supports the hypothesis that insulin increases cell
growth. Based on the major principle of cancer biology, that increased growth
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increases cellular instability and increases tumor grade, it is reasonable to then
think that insulin may increase the mitogenic growth of prostate tumors and
increase tumor grade as further stated in the hypothesis explored.53

However, recent data released by the Health Professionals Study suggest that
low-grade tumors (Gleason score <7) are associated with higher levels of insulinlike growth factor and binding protein (IGF-1 and IGFBP-3), a finding that is
counter to the proposed mechanism seen in this study and previous literature
evaluations.54 The data in the Health Professionals Study suggests that
increasing insulin levels may actually lead to lower-grade tumors in patients with
high serum insulin who develop cancer. From this, alternate hypothesis for
increased high-grade tumors in patients with elevated insulin exposure should be
further investigated, including the effect of DM on testosterone. Diabetes is linked
with lower levels of circulating testosterone, a known stimulatory agent of
prostate cancer growth. Further, testosterone has been associated with higher
grade tumors, a finding that supports what was seen in the studies by Hong and
DeNuzio.55-57 As demonstrated there are conflicting reports, and potentially
conflicting underlying biochemical mechanisms regarding the effect of diabetes
on prostate tumor grade. This highlights the importance of further study in this
area with clear measurement of the effect of serum insulin, insulin/IGFR-1
receptors and testosterone on tumor grade.
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Looking at the effects between cancer and insulin in diabetic patients in
epidemiologic data, the presence of diabetes has been shown to increase the
risk of high grade prostate tumor development, a finding that is not supported by
this analysis. Hong et al. found that in patients undergoing prostate biopsy, those
with self-reported DM were found to have a 1.54 times higher odds of developing
tumors with Gleason score ≥7.15 Similarly, De Nunzio et al. recently published a
similar study that found that patients with metabolic syndrome (defined by the
ATPIII criteria – the measured presence of 3 of the following: abdominal obesity,
hypertriglyceridemia, low high-density lipoprotein cholesterol, hypertension or
high fasting blood glucose) had a 3.82 times higher risk of high-grade tumors
(Gleason ≥7).40 While both of these analyses demonstrate increased grade
tumors in diabetic patients, the methods of defining diabetes are subject to bias
or are limited by one-time evaluation, potentially altering the results.

Other studies on the effect of DM on tumor grade report findings more similar to
what is seen here – diabetes potentially decreases the odds of high grade
prostate tumor development. Gong et al. reported a decreased in the odds of
higher-grade tumors in patients with self-reported DM (OR=0.72 (0.55-0.94)),
although again the definition of DM in these patients is subject to recall bias.
Additionally in Gong’s analysis, patients with higher BMI and weight also were
found to have an increased odds of high-grade tumor development.6 Previous
studies evaluating the effect of metabolic syndrome have found similar results,
independent of the effects of DM and insulin exposure, most likely through
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alterations in lipid and androgen metabolism.58 Farwell et al. recently reported a
10% increase in the risk of high-grade tumors in patients with elevated baseline
total cholesterol, while Llaverias et al. found that mice fed high-fat/highcholesterol diets had increased cellular proliferation and metastatic spread.59,60
Although the models within this study were unable to account for BMI and weight,
hypercholesterolemia was not found to have an effect on tumor grade or
progression, contrary to previous analysis. These findings suggest that the
interaction between DM, other factors in metabolic syndrome, serum insulin and
tumor growth is complex.
Although epidemiologic evidence exists suggesting that the use of antidiabetic
therapy may alter the development of prostate tumors, again, no evidence exists
that these agents alter tumor grade. In this evaluation, the use of insulin
stimulating agents was associated with a slight increase in high grade tumors
while non-stimulating agents were associated with a lower grade tumor
compared to those without diabetes. While this is not statistically significant, this
does provide evidence that perhaps the increase in serum insulin seen may lead
to increased mitogenic effects. This study was only able to access data from the
Kentucky Medicaid database over a 5 year period. Evaluation in a larger
database, such as the Veteran’s Administration databases may provide further
clarity on the effect of diabetic medication use on the development of high-grade
prostate tumors.
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Similarly, the difference in the time to tumor progression based on the use of
antidiabetic medications has not been previously evaluated in the literature.
Overall, this study found a potentially lower risk of tumor progression in those
using TZDs, metformin or low-dose insulin compared to non-diabetics and a
higher risk of progression in those using sulfonylureas or high-dose insulin
compared to non-diabetics. Although this was not statistically significant, this
observed phenomena may be due in part to independent anti-tumor affects of
metformin and TZDs outside of their effects on serum insulin. Metformin has
been shown inhibit in-vitro growth of prostate cell lines through AMPK activation
and mTOR inhibiton.61 Thiazolidinediones have also been shown to have
independent anti-tumor activity in vitro. This effect is thought to be primarily
through the activation of PPAR-γ, although PPAR-γ independent mechanisms
have also been suggested.62 Although sulfonylureas have not yet been shown to
have antitumor effects, it is thought that the effects on increased tumor risk and
mortality seen with sulfonylureas may be a statistical abnormality due to the
comparison to those with known anti-tumor activity.63 In this study metformin and
TZDs were associated with a potentially decreased time to progression, while
sulfonylureas had a slight increase in progression. Since the anti-tumor effects
were unable to be accounted for it is difficult to ascertain if the effects seen were
a result of the effect on insulin, or a modification of alternate tumorgenic cellular
pathways by diabetic medications.

30

Alternate models found an overall decrease in tumor progression in patients with
elevated and physiologic insulin exposure compared to those without DM. Similar
to the results of the primary evaluation, this was not statistically significant, but
leads to interesting observations on the effect of DM on tumor progression. In
addition to potential anti-tumor effects of diabetic medications, the decrease in
progression risk in those with elevated exposure may indicated a protective effect
of physiologic changes in diabetic patients. Vascular changes are common in
diabetics, often leading to numerous complications on end-organs. Post-hoc
analysis demonstrated that overall case patients in both groups had a lower
incidence of metastatic disease than non-diabetics, indicating that despite
potentially higher grade at diagnosis, diabetics may have less metastatic spread
due to poor vascularization. This hypothesis could not be evaluated in this
analysis, but should continue to be investigated in future studies.

In addition to the effects of antidiabetic agents, several covariates were found to
alter the time to tumor progression. Patients with longer durations of DM prior to
tumor diagnosis were found to have an increased risk of progression, adjusted
for use of different diabetic medications. Previous studies have shown a
decreased risk of tumor development in those with longer duration of DM,
although the effect of this on progression in unknown.13,14 Future study in this
area should adjust for actual serum levels since it appears that there is a
disparate effect seen in patients with changing insulin exposures.
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Corticosteroid use was consistently found to reduce the risk of progressive
disease, a finding that is not well evaluated in the literature. While corticosteroids
today are primarily used to reduce the inflammation and pain of metastatic
lesions, early studies suggested that they may play a role in inhibiting adrenalproduced testosterones. 64 Short term corticosteroid use may have no effect on
testosterone levels, but long term use in older patients has been shown to have a
dose-dependent decrease in serum testosterone.65,66 Within this analysis,
steroids were used across all metastatic sites, including some use in those
without known metastatic disease. The potential decrease in serum testosterone
may have led to delayed progression within these patients, although will need to
be further studied.

Although bisphosphonates are typically shown to limit tumor progression, this
analysis found that patients using these agents had a significantly increased risk
of progression. Bisphosphonates have been shown in numerous cellular studies
to inhibit cell signaling pathways that are critical to tumor proliferation, invasion
and adhesion.38,67,68 Conversely, in-vivo mouse models have shown that the use
of prophylactic and treatment zoledronic acid were not associated with
decreased tumor growth or metastatic spread.69 Although human studies have
demonstrated the effect of bisphosphonates to improve quality of life and reduce
skeletal-related events in prostate cancer patients, the use of these agents is
typically limited to those with metastatic or highly aggressive disease. The
increase risk of progression due to bisphosphonate use may be an artifact of the
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correlation of bisphosphonate use to metastatic patients with high tumor burden
in bone, a characteristic which could not be discerned in this dataset. Since this
effect was not seen until stage was no longer evaluated as a covariate, it is
possible that the risk seen is merely a measure of the risk of progression in
higher stage disease.

All studies have strength and limitations. This study had several factors that may
have limited the ability to detect a difference in tumor grade and progression
between users of different antidiabetic medications. First, the sample size was
small for the type of large-cohort analysis conducted. Although the trends seen in
regards to the effects of insulin exposure on tumor grade support the hypothesis,
the lack of power in this analysis leads to inconclusive results. Additionally,
changes in endogenous secretion of insulin in patients on anti-diabetic
medications could not be accounted for. This lack of quantitation of insulin may
have led to unknown misclassification within the exposure groups, potentially
skewing the results. Although the duration of DM was accounted for, it was
limited to what was observed during the study period – thus any long-term effects
of diabetes treatment prior to study initiation is unaccounted for. Further, as
discussed above, this study was unable to adjust for potential independent
chemotherapeutic effects of anti-diabetic treatments. Finally, analysis using large
billing databases is always subject to misclassification, although this was limited
through a thorough review of the available data.
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SECTION FIVE: CONCLUSION
The use of antidiabetic medications that cause high insulin exposure did not
increase the grade of prostate tumor upon diagnosis or decrease the time to
tumor progression in this analysis. Although the results were are inconclusive this
data provides needed insight into the interactions between diabetes treatments
and the development and progression of prostate tumors. While this study was
underpowered to provide any conclusive results, the hypothesis remains credible
and should continue to be investigated through larger database analyses, as well
as potential prospective studies. As seen, there is a multitude of factors that
interplay within the proposed mechanism to lead to tumor development and
progression. Future analysis should consider an evaluation of serum insulin,
weight, BMI, lipids (cholesterol, HDL, LDL, TG), testosterone, and IGFR-1
expression on pathologic samples, along with robust medical histories (including
complete antidiabetic and lipid-lowering agents, bisphosphonate use, hormone
therapy, and steroid medications histories) in order to fully evaluate the effect of
medications on prostate tumors. Through a better characterization of these
interactions, future treatment of patients with diabetes and prostate cancer may
be optimized and overall health outcomes improved.
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Appendix Table 1: NDC Codes used to determine medication classifications
Drug

Insulin
Exposure
Group
Excluded

Medication
Class

NDC

Antidiabetic

Elevated
Insulin
Exposure
Excluded

Antidiabetic

26286148, 26286151,
26286251, 26286351,
16250000000
50110000000

Antidiabetic

66780000000

Glimepiride

Elevated
Insulin
Exposure

Antidiabetic

Glipizide

Elevated
Insulin
Exposure

Antidiabetic

Glyburide

Elevated
Insulin
Exposure

Antidiabetic

39022110, 39022210,
39022211, 39022310,
39022311, 55110000000,
63300000000,
66990000000
49155066, 49155073,
49156066, 49156073,
49162030, 172400000,
378100000, 591000000,
591100000, 781100000,
51080000000,
51290000000,
52540000000,
59760000000,
60510000000,
62040000000
9017105, 9035204,
9344903, 39005210,
93803501, 93834301,
93834305, 93834310,
93834401, 93834405,
93834410, 93936401,
93936405, 93936410,
93943301, 93943305,
93947753, 378100000,
781100000, 38250000000,
38250000000,
51080000000,
55370000000,
55950000000,
59760000000,
59760000000,
67250000000

Acarbose

Chlorpropamide

Exenatide
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Glyburide/metformin

Elevated
Insulin
Exposure

Antidiabetic

Insulin

Elevated
Insulin
Exposure if
avgqty >20mL
Q30days
(determined
on avg supply
since such
variation in
day supply.
This is based
on
0.8units*85kg
=68units/day;
100 units/mL=
~20mL/month)

Antidiabetic

Metformin

Physiologic
Insulin
Exposure if
avgqty <20mL
Q30days
Physiologic
Insulin
Exposure

Antidiabetic
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87607211, 87607311,
87607411, 93571201,
93571205, 172600000,
228300000, 781500000,
49880000000
2751001, 2751101,
2821501, 2831001,
2831501, 2861501,
2871501, 2872559,
2873059, 2877059,
2879459, 69005053,
88222033, 88222060,
169000000, 169200000,
169200000, 169200000,
169200000, 169200000,
169200000, 169300000,
169300000, 169400000,
169600000, 169800000,
59060000000

87606005, 87606010,
87606313, 87607005,
87607010, 87607111,
87607112, 93104801,
93104805, 93104810,
93104901, 93104905,
93721401, 93721405,
93726701, 93726710,
172400000, 172400000,
185000000, 185400000,
228300000, 378000000,
555000000, 591200000,
591300000, 781500000,
904600000, 49880000000,
49880000000,
51080000000,
53490000000,
57660000000,

Miglitol

Excluded

Antidiabetic

Nateglinide
Pioglitazone

Excluded
Physiologic
Insulin
Exposure
Physiologic
Insulin
Exposure
Excluded
Physiologic
Insulin
Exposure
Physiologic
Insulin
Exposure
Excluded
Physiologic
Insulin
Exposure

Antidiabetic
Antidiabetic

60510000000,
60510000000,
62020000000,
62040000000,
62040000000,
62580000000,
62760000000,
63300000000,
65860000000,
68380000000
9501201, 9501301,
9501401
78035105, 78035205
64760000000

Antidiabetic

64760000000

Antidiabetic
Antidiabetic

169000000
29315818, 29315913,
29315918, 29315920,
29316013, 29316020
7316418, 7316718,
7316720, 7316818,
7316820
6027731
71035223, 71035315,
71035323, 71035720

Pioglitazone/
metformin
Repaglinide
Rosiglitazone

Rosiglitazone/
metformin
Sitagliptin
Troglitazone

Bicalutamide
Flutamide
Ketoconazole
Nilutamide
Goserelin
Leuprolide
Alendronate

Antidiabetic

Antidiabetic
Antidiabetic

Antiandrogen/
GNRH agonist
Antiandrogen/
GNRH agonist
Antiandrogen/
GNRH agonist
Antiandrogen/
GNRH agonist
Antiandrogen/
GNRH agonist
Antiandrogen/
GNRH agonist
Bisphosphonate
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93022056, 310100000
85052506, 93712086,
172500000, 555100000
93090001, 51670000000
88111035, 88111114
310100000
300200000, 300300000,
300400000
6003121, 6003144,
6007744, 6092531,
6093628, 6093631,
6093658, 93517120,

Ibandronate
Pamidronate
Risedronate
Zoledronic acid
Dexamethasone

Bisphosphonate
Bisphosphonate
Bisphosphonate
Bisphosphonate
Steroids

Fludrocortisone

Steroids

Hydrocortisone

Steroids

Methylprednisolone

Steroids

Prednisolone

Steroids

Prednisone

Steroids
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93517144
4018682
83260901, 55390000000
149000000
78035084, 78038725
54317763, 54418025,
54418125, 54418325,
54418425, 54817525,
95008651, 402100000,
517500000, 603300000,
641000000, 703400000,
904000000, 49880000000,
60430000000,
63320000000
3042950, 115700000,
555100000
6061968, 9001201,
9003101, 9082501,
143100000, 536400000,
574200000, 677000000,
39820000000
9019009, 9019016,
9030602, 9307301,
9307303, 9347501,
74568502, 182100000,
254400000, 527100000,
536400000, 555000000,
591100000, 603500000,
677100000, 781500000,
49880000000,
51290000000,
52540000000,
59750000000,
59760000000,
62270000000,
63300000000
58180000000,
59200000000,
60430000000,
65580000000
9004501, 9004502,
9004516, 9016501,
9016502, 9019301,
9019302, 9038801,
54001720, 54001725,
54001729, 54001820,

54001825, 54001829,
54472825, 54472831,
54472925, 54472929,
54473025, 54473029,
54473325, 54474125,
54872425, 54872525,
54872625, 54874025,
143100000, 182100000,
254500000, 259000000,
364000000, 536400000,
591500000, 603500000,
677000000, 677100000,
904200000, 51080000000,
52540000000,
53490000000
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Appendix Table 2: Multivariate Analysis of Odds of Developing High Gleason
Score Based on Insulin Exposure (n=236; eliminating Charlson score as a
covariate)
Odds
Ratio

95% Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.68 (0.31-1.50)
Rural
0.93 (0.49-1.73)
Corticosteroid Use (before dx)
No Reference
Yes
1.27 (0.21-7.75)
Diabetes Group
No Diabetes Reference
Elevated insulin exposure
0.98 (0.48-1.97)
Physiologic insulin exposure
0.56 (0.21-1.49)
Physiologic compared to
elevated
0.56 (0.22-1.48)
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0.338
0.808

0.798

0.946
0.245
0.244

Appendix Table 3: Multivariate Analysis of Odds of Developing High Gleason
Score Based on Insulin Exposure (n=236; uses presence of hypertension and
hypercholesterolemia as a measure of comorbid disease)
Odds
Ratio

95% Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.67 (0.30-1.48)
Rural
0.90 (0.46-1.73)

0.318
0.741

Presence of HTN
No
Yes
Presence of Hypercholesterolemia
No
Yes
Corticosteroid Use (before dx)
No
Yes
Diabetes Group
No Diabetes
Elevated insulin exposure
Physiologic insulin exposure
Physiologic compared to elevated

Reference
0.67 (0.31-1.45)

0.306

Reference
1.12 (0.61-2.04)

0.715

Reference
1.17 (0.19-7.26)

0.867

Reference
1.00 (0.49-2.08)
0.59 (0.22-1.60)
0.59 (0.22-1.57)

0.988
0.304
0.293
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Appendix Table 4: Multivariate Analysis of Odds of Developing High Gleason
Score Based on Insulin Exposure (n=61; includes measure of duration of DM
diagnosis prior to prostate cancer)
Odds
Ratio

95% Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.76 (0.13-4.48)
Rural
0.34 (0.05-2.29)

0.762
0.267

Presence of HTN
No Reference
Yes Dropped – all those without HTN (#2) did
not have a high Gleason
Presence of Hypercholesterolemia
No Reference
Yes
2.54 (0.43-14.94)
0.302
Corticosteroid Use (before dx)
No Reference
Yes
2.04 (0.10-41.4)
0.641
Diabetes Group
No Diabetes Reference
Elevated insulin exposure N/A
N/A
N/A
Physiologic insulin exposure
0.49 (0.15-1.65)
0.250
Physiologic compared to elevated
N/A N/A
N/A
Duration of DM diagnosis prior to
PCa(yr)
0.87 (0.58-1.33)
0.528
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Appendix Table 5: Multivariate Analysis of Hazard of Prostate Cancer
Progression (n=294; eliminating Charlson score as a covariate)
Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.79 (0.40-1.55)
Rural
0.80 (0.47-1.36)

0.496
0.416

Stage
Localized
Regional
Distant Metastases
Unknown/unstageable
Corticosteroid Use
(prior to recurrence)
No
Yes
Bisphosphonate Use
(prior to recurrence)
No
Yes
Antiandrogen/GNRH agonist
(prior to recurrence)
No
Yes
Diabetes Group
No Diabetes
Elevated insulin exposure
Physiologic insulin exposure
Physiologic compared to
elevated

Reference
0.94 (0.36-2.41)
0.95 (0.47-1.90)
0.77 (0.28-2.15)

0.890
0.881
0.623

Reference
0.53 (0.27-1.03)

0.060

Reference
2.36 (1.21-4.59)

0.012

Reference
1.02 (0.61-1.70)

0.950

Reference
0.95 (0.54-1.68)
0.59 (0.23-1.51)

0.872
0.272

0.60 (0.24-1.51)

0.278
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Appendix Table 6: Multivariate Analysis of Hazard of Prostate Cancer
Progression (n=491; eliminating Charlson score and stage as a covariate)
Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
1.14 (0.68-1.91)
Rural
0.85 (0.56-1.30)

0.622
0.464

No Reference
Yes
0.56 (0.34-0.93)

0.025

Corticosteroid Use
(prior to recurrence)

Bisphosphonate Use
(prior to recurrence)
No Reference
Yes
2.44 (1.46-4.06)
Antiandrogen/GNRH agonist use
(prior to recurrence)
No Reference
Yes
1.20 (0.79-1.83)
Diabetes Group
No Diabetes Reference
Elevated insulin exposure
0.75 (0.46-1.20)
Physiologic insulin exposure
0.53 (0.26-1.10)
Physiologic compared to
elevated
0.56 (0.27-1.16)
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0.001

0.390

0.231
0.086
0.117

Appendix Table 7: Multivariate Analysis of Hazard of Prostate Cancer
Progression (n=491; uses presence of hypertension and hypercholesterolemia as
a measure of comorbid disease)
Variable

Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
1.10 (0.65-1.85)
Rural
0.79 (0.51-1.23)

0.728
0.300

No Reference
Yes
0.87 (0.52-1.48)

0.618

Presence of HTN

Presence of
Hypercholesterolemia
No
Yes
Presence of metastases at
diagnosis
No
Yes
Corticosteroid Use
(prior to recurrence)
No
Yes
Bisphosphonate Use
(prior to recurrence)
No
Yes
Antiandrogen/GNRH agonist
(prior to recurrence)
No
Yes
Diabetes Group
No Diabetes
Elevated insulin exposure
Physiologic insulin
exposure
Physiologic compared to
elevated

Reference
1.35 (0.92-1.98)

0.127

Reference
0.93 (0.48-1.81)

0.840

Reference
0.58 (0.35-0.97)

0.037

Reference
2.41 (1.44-4.04)

0.001

Reference
1.25 (0.81-1.91)

0.311

Reference
0.73 (0.45-1.18)

0.198

0.50 (0.24-1.06)

0.070

0.55 (0.26-1.14)

0.106
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Appendix Table 8: Multivariate Analysis of Hazard of Prostate Cancer
Progression (n=153; includes measure of duration of DM diagnosis prior to
prostate cancer)
Variable

Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
2.19 (0.79-6.08)
Rural
0.57 (0.20-1.66)

0.133
0.303

Presence of HTN
No
Yes
Presence of Hypercholesterolemia
No
Yes
Presence of metastases at
diagnosis
No
Yes
Corticosteroid Use
(prior to recurrence)
No
Yes
Bisphosphonate Use
(prior to recurrence)
No
Yes
Antiandrogen/GNRH agonist use
(prior to recurrence)
No
Yes
Diabetes Group
No Diabetes
Elevated insulin exposure
Physiologic insulin exposure
Physiologic compared to elevated
Duration of DM diagnosis prior to
PCa (years)

Reference
1.17 (0.14-9.63)

0.880

Reference
1.37 (0.59-3.20)

0.466

Reference
1.07 (0.13-8.58)

0.947

Reference
0.31 (0.08-1.12)

0.073

Reference
4.16 (1.28-13.5)

0.017

Reference
1.04 (0.43-2.53)

0.925

Reference
N/A
N/A
0.58 (0.24-1.41)
N/A
N/A
1.26 (1.02-1.55)
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N/A
0.230
N/A
0.031

Appendix Table 9: Multivariate Analysis of Odds of Developing High Gleason
Score Based on Presence of Diabetes (n=133)
Odds
Ratio

95% Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.52 (0.17-1.57)
Rural
0.75 (0.31-1.83)
Charlson score
1.09 (0.81-1.46)
Corticosteroid Use (before dx)
No Reference
Yes
1.44 (0.23-9.11)
Presence of DM
No Reference
Yes
0.84 (0.41-1.75)
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0.249
0.532
0.573

0.699

0.648

Appendix Table 10: Multivariate Analysis of Odds of Developing High Gleason
Score Based on Presence of Diabetes (n=236; eliminating Charlson score as a
covariate)
Odds
Ratio

95% Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.68 (0.31-1.51)
Rural
0.93 (0.50-1.74)
Corticosteroid Use (before dx)
No Reference
Yes
1.21 (0.20-7.39)
Presence of DM
No Reference
Yes
0.81 (0.44-1.49)
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0.347
0.819

0.835

0.501

Appendix Table 11: Multivariate Analysis of Odds of Developing High Gleason
Score Based on Presence of Diabetes (n=236; uses presence of hypertension
and hypercholesterolemia as a measure of comorbid disease)
Odds
Ratio

95% Confidence
Interval

p-value

Rurality
Urban
Suburban
Rural
Presence of Hypertension
No
Yes
Presence of Hypercholesterolemia
No
Yes
Corticosteroid Use (before dx)
No
Yes
Presence of DM
No
Yes

Reference
0.67 (0.30-1.49)
0.90 (0.46-1.73)

0.324
0.742

Reference
0.66 (0.30-1.43)

0.288

Reference
1.31 (0.62-2.06)

0.687

Reference
1.12 (0.18-6.92)

0.905

Reference
0.84 (0.45-1.59)

0.601
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Appendix Table 12: Multivariate Analysis of Hazard of Prostate Cancer
Progression Based on Presence of Diabetes (n=168)
Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.83 (0.32-2.17)
Rural
0.73 (0.33-1.62)
Charlson score
0.86 (0.63-1.18)
Stage
Localized Reference
Regional
1.07 (0.32-3.65)
Distant Metastases
0.97 (0.37-2.57)
Unknown/unstageable
1.76 (0.40-7.67)
Corticosteroid Use
(prior to recurrence)
No Reference
Yes
0.34 (0.13-0.86)
Bisphosphonate Use
(prior to recurrence)
No Reference
Yes
2.07 (0.65-6.55)
Antiandrogen/GNRH
agonist use
(prior to recurrence)
No Reference
Yes
0.90 (0.43-1.90)
Presence of Diabetes
No Reference
Yes
0.96 (0.49-1.87)
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0.706
0.439
0.342

0.910
0.952
0.452

0.024

0.217

0.784

0.907

Appendix Table 13: Multivariate Analysis of Hazard of Prostate Cancer
Progression Based on Presence of Diabetes (n=294; eliminating Charlson score
as a covariate)
Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
0.76 (0.39-1.49)
Rural
0.81 (0.48-1.37)

0.427
0.435

Stage
Localized
Regional
Distant Metastases
Unknown/unstageable
Corticosteroid Use
(prior to recurrence)
No
Yes
Bisphosphonate Use
(prior to recurrence)
No
Yes
Antiandrogen/GNRH
agonist use
(prior to recurrence)
No
Yes
Presence of Diabetes
No
Yes

Reference
0.98 (0.38-2.51)
0.95 (0.48-1.91)
0.80 (0.29-2.20)

0.960
0.894
0.661

Reference
0.53 (0.27-1.05)

0.068

Reference
2.38 (1.22-4.64)

0.011

Reference
1.01 (0.60-1.69)

0.973

Reference
0.84 (0.50-1.39)

0.493
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Appendix Table 14: Multivariate Analysis of Hazard of Prostate Cancer
Progression Based on Presence of Diabetes (n=491; eliminating Charlson score
and stage as a covariate)
Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban
Suburban
Rural
Corticosteroid Use
(prior to recurrence)
No
Yes
Bisphosphonate Use
(prior to recurrence)
No
Yes
Antiandrogen/GNRH
agonist use
(prior to recurrence)
No
Yes
Presence of Diabetes
No
Yes

Reference
1.11 (0.66-1.85)
0.85 (0.56-1.30)

0.694
0.451

Reference
0.57 (0.34-0.94)

0.028

Reference
2.45 (1.47-4.08)

0.001

Reference
1.20 (0.79-1.83)

0.390

Reference
0.67 (0.44-1.02)

0.062
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Appendix Table 15: Multivariate Analysis of Hazard of Prostate Cancer
Progression Based on Presence of Diabetes (n=491; uses presence of
hypertension and hypercholesterolemia as a measure of comorbid disease)
Variable

Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
1.07 (0.64-1.79)
Rural
0.79 (0.51-1.23)

0.807
0.292

No Reference
Yes
0.87 (0.51-1.47)

0.598

Presence of HTN

Presence of
Hypercholesterolemia
No
Yes
Presence of metastases at
diagnosis
No
Yes
Corticosteroid Use
(prior to recurrence)
No
Yes
Bisphosphonate Use
(prior to recurrence)
No
Yes
Antiandrogen/GNRH agonist
(prior to recurrence)
No
Yes
Presence of Diabetes
No
Yes

Reference
1.34 (0.91-1.97)

0.135

Reference
0.94 (0.49-1.82)

0.853

Reference
0.59 (0.35-0.98)

0.042

Reference
2.43 (1.45-4.07)

0.001

Reference
1.25 (0.81-1.91)

0.311

Reference
0.65 (0.42-1.00)

0.051
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Appendix Table 16: Multivariate Analysis of Hazard of Prostate Cancer
Progression Based on Presence of Diabetes (n=153; includes measure of
duration of DM diagnosis prior to prostate cancer)
Variable

Hazard
Ratio

95%
Confidence
Interval

p-value

Rurality
Urban Reference
Suburban
1.90 (0.70-5.12)
Rural
0.59 (0.21-1.67)

0.206
0.319

No Reference
Yes
0.93 (0.12-7.30)

0.945

Presence of HTN

Presence of
Hypercholesterolemia
No
Yes
Presence of metastases at
diagnosis
No
Yes
Corticosteroid Use
(prior to recurrence)
No
Yes
Bisphosphonate Use
(prior to recurrence)
No
Yes
Antiandrogen/GNRH agonist
(prior to recurrence)
No
Yes
Presence of Diabetes
No
Yes
Duration of DM diagnosis
prior to PCa (years)

Reference
1.31 (0.57-3.02)

0.520

Reference
1.11 (0.14-8.87)

0.924

Reference
0.34 (0.10-1.22)

0.099

Reference
4.09 (1.27-13.2)

0.018

Reference
1.03 (0.42-2.53)

0.942

Reference
Dropped due to collinearity with DM
time variables
1.28 (1.04-1.57)
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0.018
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